February 19, 2019
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets.
January 16, 2019
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.
December 12, 2018
Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million
December 5, 2018
Governor in Council selection processes underway
September 11, 2018
Increased spending on high cost drugs and reduced savings from generics responsible for 6.3% average growth over 2 years.